Trial Profile
A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms B-IMMUNE
- 22 Feb 2024 Status changed from active, no longer recruiting to completed.
- 11 Jul 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 11 Jul 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.